Abstract Number: 1299 • ACR Convergence 2023
Rheumatoid Arthritis Patients Who Never Use a Biological During Their Disease Course Represent a Subgroup of Patients Likely to Achieve Sustained DMARD-free Remission
Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) complete cessation of DMARDs is not advisable due to a high…Abstract Number: 1315 • ACR Convergence 2023
Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies
Background/Purpose: Active rheumatoid arthritis (RA) is associated with a higher prevalence of insulin resistance (IR). Dysregulation of adipokines driven by low-level systemic inflammation plays a…Abstract Number: 1332 • ACR Convergence 2023
Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)
Background/Purpose: The efficacy of filgotinib (FIL) for treating RA has been demonstrated in clinical trials. Real-world data are valuable to assess patient-reported outcomes such as…Abstract Number: 1356 • ACR Convergence 2023
Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Women with systemic rheumatic diseases (SRDs), particularly those with SLE, may be more vulnerable to HPV infection and HPV-related cervical cancer. However, HPV testing…Abstract Number: 1678 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
Background/Purpose: In the ORAL Surveillance trial, cancer risk was higher among patients with rheumatoid arthritis (RA) on tofacitinib, a Janus kinase inhibitor (JAKi), compared to…Abstract Number: 1733 • ACR Convergence 2023
Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available…Abstract Number: 1749 • ACR Convergence 2023
Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…Abstract Number: 1765 • ACR Convergence 2023
Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
Background/Purpose: Cigarette smoking (CS) is a major environmental risk factor for the development of Rheumatoid Arthritis (RA), and is associated with the development of RA…Abstract Number: 020 • 2023 Pediatric Rheumatology Symposium
Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model
Background/Purpose: Most rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) patients experience episodic arthritis flares and require life-long medications to control their disease. We observed…Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…Abstract Number: L03 • ACR Convergence 2022
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). We hypothesized that peresolimab binding to PD-1,…Abstract Number: L06 • ACR Convergence 2022
Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher risk of…Abstract Number: 0009 • ACR Convergence 2022
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cell, CD19 expressing plasma cell, and plasmablast activity and is expected to provide clinical benefit across…Abstract Number: 0076 • ACR Convergence 2022
Real World Rheumatology Practice of Biologic Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: A Four-year Cohort Study Using a National Claims Database
Background/Purpose: There is a growing concern over the rise of polypharmacy, arguably one of the most pressing prescribing challenges. The option of biologic monotherapy is…
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 188
- Next Page »